Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preoperative Nivolumab in High-Risk Renal Cell Carcinoma
NCT02595918Phase 1Terminated
- Sponsor
- National Cancer Institute
- Start
- May 2016
- Primary completion
- Aug 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of nivolumab in renal cell carcinoma (RCC), sponsored by National Cancer Institute. Primary endpoint: Feasibility of preoperative nivolumab up to 8 weeks. Started May 2016; status: terminated.
02
Drugs
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT02595918.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02595918.